SCN1A and Dravet syndrome: The anticonvulsant activity of SB2193 was first assayed in the Scn1a+/− mouse model which recapitulates the characteristic symptoms of Dravet syndrome, including the development of spontaneous seizures and premature mortality (Miller et al., 2014).